JP4879492B2 - 疾患の治療のためのキナーゼ阻害剤 - Google Patents

疾患の治療のためのキナーゼ阻害剤 Download PDF

Info

Publication number
JP4879492B2
JP4879492B2 JP2004570761A JP2004570761A JP4879492B2 JP 4879492 B2 JP4879492 B2 JP 4879492B2 JP 2004570761 A JP2004570761 A JP 2004570761A JP 2004570761 A JP2004570761 A JP 2004570761A JP 4879492 B2 JP4879492 B2 JP 4879492B2
Authority
JP
Japan
Prior art keywords
mmol
group
alkyl
dihydro
indol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004570761A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006512400A (ja
JP2006512400A5 (enExample
Inventor
スティーブン・ダブリュー・アンドリュース
マイケル・イー・ガースト
シャリン・グオ
ジョナサン・ジェイ・ヒーバート
トーマス・マローン
ジュリー・エイ・ワースター
クラレンス・ユージーン・ハル・ザ・サード
ユアン−シン・グオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/307,097 external-priority patent/US6699863B1/en
Priority claimed from US10/389,416 external-priority patent/US6747025B1/en
Application filed by Allergan Inc filed Critical Allergan Inc
Priority claimed from PCT/US2003/036988 external-priority patent/WO2004050621A2/en
Publication of JP2006512400A publication Critical patent/JP2006512400A/ja
Publication of JP2006512400A5 publication Critical patent/JP2006512400A5/ja
Application granted granted Critical
Publication of JP4879492B2 publication Critical patent/JP4879492B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
JP2004570761A 2002-11-27 2003-11-19 疾患の治療のためのキナーゼ阻害剤 Expired - Fee Related JP4879492B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US30697502A 2002-11-27 2002-11-27
US10/307,097 2002-11-27
US10/307,097 US6699863B1 (en) 2002-11-27 2002-11-27 Kinase inhibitors for the treatment of disease
US10/306,975 2002-11-27
US10/389,416 2003-03-13
US10/389,416 US6747025B1 (en) 2002-11-27 2003-03-13 Kinase inhibitors for the treatment of disease
PCT/US2003/036988 WO2004050621A2 (en) 2002-11-27 2003-11-19 Indol derivatives and their use as kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011123575A Division JP2011225582A (ja) 2002-11-27 2011-06-01 疾患の治療のためのキナーゼ阻害剤

Publications (3)

Publication Number Publication Date
JP2006512400A JP2006512400A (ja) 2006-04-13
JP2006512400A5 JP2006512400A5 (enExample) 2006-11-02
JP4879492B2 true JP4879492B2 (ja) 2012-02-22

Family

ID=45041406

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004570761A Expired - Fee Related JP4879492B2 (ja) 2002-11-27 2003-11-19 疾患の治療のためのキナーゼ阻害剤
JP2011123575A Pending JP2011225582A (ja) 2002-11-27 2011-06-01 疾患の治療のためのキナーゼ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011123575A Pending JP2011225582A (ja) 2002-11-27 2011-06-01 疾患の治療のためのキナーゼ阻害剤

Country Status (1)

Country Link
JP (2) JP4879492B2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011225582A (ja) * 2002-11-27 2011-11-10 Allergan Inc 疾患の治療のためのキナーゼ阻害剤

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7928136B2 (en) * 2006-09-11 2011-04-19 Curis, Inc. Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001016130A1 (de) * 1999-08-27 2001-03-08 Boehringer Ingelheim Pharma Kg Substituierte indolinone als tyrosinkinase inhibitoren
WO2001027081A1 (de) * 1999-10-13 2001-04-19 Boehringer Ingelheim Pharma Kg In 6-stellung substituierte indolinone, ihre herstellung und ihre verwendung als arzneimittel
WO2001090104A2 (en) * 2000-05-24 2001-11-29 Pharmacia & Upjohn Company -(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as modulators of protein kinases
JP2002511449A (ja) * 1998-04-15 2002-04-16 ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト 新規な置換インドリノン、それらの調製及び医薬組成物としてのそれらの使用
WO2002036564A1 (de) * 2000-11-01 2002-05-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sulfonylamino substituierte 3-(aminomethyliden)-2-indolinone als inhibitoren der zellproliferation
JP2002516310A (ja) * 1998-05-29 2002-06-04 スージェン・インコーポレーテッド ピロール置換２−インドリノンタンパク質キナーゼ阻害剤
JP2002516906A (ja) * 1998-06-04 2002-06-11 ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト 新規置換インドリノン、それらの調製及び医薬組成物としてのそれらの使用
JP2002522452A (ja) * 1998-08-04 2002-07-23 スージェン・インコーポレーテッド 蛋白質キナーゼの調節剤３−メチリデニル−２−インドリノン
JP2002523455A (ja) * 1998-08-31 2002-07-30 スージェン・インコーポレーテッド 蛋白質キナーゼ活性の調節剤としての幾何学的に制限された２−インドリノン誘導体
JP2002525356A (ja) * 1998-09-25 2002-08-13 ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト 新規置換インドリノン、それらの調製及び薬物としてのそれらの使用
CN1365972A (zh) * 2001-01-19 2002-08-28 中国人民解放军军事医学科学院毒物药物研究所 吲哚类衍生物及其抗肿瘤用途
WO2002081445A1 (de) * 2001-04-06 2002-10-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg In 6-stellung substituierte indoline und ihre verwendung als kinase-inhibitoren
JP2005537276A (ja) * 2002-07-23 2005-12-08 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト ６−置換インドリノン誘導体、その製法及び医薬組成物としての使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
JP4879492B2 (ja) * 2002-11-27 2012-02-22 アラーガン、インコーポレイテッド 疾患の治療のためのキナーゼ阻害剤

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002511449A (ja) * 1998-04-15 2002-04-16 ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト 新規な置換インドリノン、それらの調製及び医薬組成物としてのそれらの使用
JP2002516310A (ja) * 1998-05-29 2002-06-04 スージェン・インコーポレーテッド ピロール置換２−インドリノンタンパク質キナーゼ阻害剤
JP2002516906A (ja) * 1998-06-04 2002-06-11 ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト 新規置換インドリノン、それらの調製及び医薬組成物としてのそれらの使用
JP2002522452A (ja) * 1998-08-04 2002-07-23 スージェン・インコーポレーテッド 蛋白質キナーゼの調節剤３−メチリデニル−２−インドリノン
JP2002523455A (ja) * 1998-08-31 2002-07-30 スージェン・インコーポレーテッド 蛋白質キナーゼ活性の調節剤としての幾何学的に制限された２−インドリノン誘導体
JP2002525356A (ja) * 1998-09-25 2002-08-13 ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト 新規置換インドリノン、それらの調製及び薬物としてのそれらの使用
WO2001016130A1 (de) * 1999-08-27 2001-03-08 Boehringer Ingelheim Pharma Kg Substituierte indolinone als tyrosinkinase inhibitoren
WO2001027081A1 (de) * 1999-10-13 2001-04-19 Boehringer Ingelheim Pharma Kg In 6-stellung substituierte indolinone, ihre herstellung und ihre verwendung als arzneimittel
WO2001090068A2 (en) * 2000-05-24 2001-11-29 Sugen, Inc. Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use a modulators of protein kinases
WO2001090104A2 (en) * 2000-05-24 2001-11-29 Pharmacia & Upjohn Company -(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as modulators of protein kinases
WO2002036564A1 (de) * 2000-11-01 2002-05-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sulfonylamino substituierte 3-(aminomethyliden)-2-indolinone als inhibitoren der zellproliferation
CN1365972A (zh) * 2001-01-19 2002-08-28 中国人民解放军军事医学科学院毒物药物研究所 吲哚类衍生物及其抗肿瘤用途
WO2002081445A1 (de) * 2001-04-06 2002-10-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg In 6-stellung substituierte indoline und ihre verwendung als kinase-inhibitoren
JP2005537276A (ja) * 2002-07-23 2005-12-08 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト ６−置換インドリノン誘導体、その製法及び医薬組成物としての使用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011225582A (ja) * 2002-11-27 2011-11-10 Allergan Inc 疾患の治療のためのキナーゼ阻害剤

Also Published As

Publication number Publication date
JP2011225582A (ja) 2011-11-10
JP2006512400A (ja) 2006-04-13

Similar Documents

Publication Publication Date Title
US7531665B2 (en) Kinase inhibitors for the treatment of disease
US7060844B2 (en) (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
EP2473513B1 (en) Compounds as tyrosine kinase modulators
US6699863B1 (en) Kinase inhibitors for the treatment of disease
JP2010116411A (ja) キナーゼ阻害物質としての３−（アリールアミノ）メチレン−１，３−ジヒドロ−２ｈ−インドール−２−オン類
US7393870B2 (en) 3-(heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors
EP1902027A1 (en) 3-spir0cycl0pr0pyl2-0xind0le kinase inhibitors
US8558002B2 (en) Sulfoximines as kinase inhibitors
JP4879492B2 (ja) 疾患の治療のためのキナーゼ阻害剤
ES2292329B2 (es) Inhibidores de quinasa para el tratamiento de enfermedades.
US20060004084A1 (en) (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
US8455529B2 (en) Kinase inhibitors
EP1902024A2 (en) Kinase inhibitors
WO2003027109A1 (en) 3-(heteroarylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060914

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100420

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100720

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100727

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100819

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100826

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100917

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101020

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20101020

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110601

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111011

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20111011

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111101

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111130

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141209

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees